Welcome to Mimetogen Pharmaceuticals
November 28, 2012
Mimetogen Pharmaceuticals Inc. Announces Issuance of Key US Patent Protecting the Use of MIM-D3 to Treat Dry Eye Disease
  Read more...
January 05, 2012
Mimetogen Pharmaceuticals Inc. Appoints Kim Brazzell, Ph.D. as Chief Medical Officer
  Read more...
June 26, 2011
Mimetogen Pharmaceuticals Inc. Announces Positive Top Line Data from Phase II Clinical Trial of MIM-D3 for Dry Eye Disease
  Read more...
1000 de La Gauchetière Street West, Suite 900. Montréal, Québec, H3B 5H4, Canada
© COPYRIGHT 2006 - Mimetogen Pharmaceuticals - ALL RIGHTS RESERVED